L. Piller

发表

Adaptive group‐sequential design with population enrichment in phase 3 randomized controlled trials with two binary co‐primary endpoints

B. Davis, Jianchang Lin, L. Moyé, 2019, Statistics in Medicine.

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

B. Davis, Jackson T. Wright, J. Williamson, 2002, JAMA.

Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 2: Statistical considerations.

G. Ball, L. Piller, 2011, Contemporary clinical trials.

Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial.

Doris A Taylor, B. Byrne, D. Gordon, 2011, JAMA.

Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial.

Doris A Taylor, D. Gordon, T. Henry, 2012, JAMA.

Long-Term Effects of Incident Diabetes Mellitus on Cardiovascular Outcomes in People Treated for Hypertension: The ALLHAT Diabetes Extension Study

B. Davis, Jackson T. Wright, P. Whelton, 2012, Circulation. Cardiovascular quality and outcomes.

Antihypertensive Prescriptions for Newly Treated Patients Before and After the Main Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Results and Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Guidel

P. Whelton, J. Cutler, W. Cushman, 2009, Hypertension.

Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease.

B. Davis, G. Marcus, C. Albert, 2016, JAMA internal medicine.

Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells).

Doris A Taylor, S. Berceli, J. Lima, 2017, Circulation.

Pressure Control in Hispanics in the Antihypertensive and Lipid-Lowering

N. Wong, C. Ford, K. Margolis, 2007 .

Blood Pressure Control in Hispanics in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

Jackson T. Wright, W. Cushman, N. Wong, 2007, Hypertension.

Clinical Significance of Incident Hypokalemia and Hyperkalemia in Treated Hypertensive Patients in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

B. Davis, S. Oparil, W. Cushman, 2012, Hypertension.

Risk and Clinical Risk Factors Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Squamous Cell Carcinoma Survivors.

Xianglin L. Du, A. Garden, C. Fuller, 2021, JAMA otolaryngology-- head & neck surgery.

Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT.

B. Davis, Jackson T. Wright, E. Soliman, 2017, Journal of the National Medical Association.

Hypertension Control Among Newly Treated Patients Before and After Publication of the Main ALLHAT Results and JNC 7 Guidelines

P. Whelton, J. Cutler, W. Cushman, 2012, Journal of clinical hypertension.

Incidence and Predictors of Angioedema in Elderly Hypertensive Patients at High Risk for Cardiovascular Disease: A Report From the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

B. Davis, S. Oparil, H. Black, 2006, Journal of clinical hypertension.

P-444: Validation of heart failure events in ALLHAT participants assigned to doxazosin

B. Davis, J. Williamson, J. Cutler, 2001 .

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial

Scott T. Miller, Jamie L. Coleman, B. Davis, 2016, The Lancet.

TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, randomised controlled trial

Scott T. Miller, Jamie L. Coleman, B. Davis, 2015, Lancet (London, England).

Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.

B. Davis, M. Pfeffer, J. Rouleau, 1999, Circulation.

Response to Letter Regarding Article, “Role of Diuretics in the Prevention of Heart Failure: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)”

B. Davis, J. Cutler, M. Proschan, 2006 .

Autologous Cardiac Stem Cell Injection in Patients with Hypoplastic Left Heart Syndrome (CHILD Study)

B. Davis, W. Mahle, Michael E. Davis, 2022, Pediatric Cardiology.

Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction.

Doris A Taylor, B. Byrne, D. Gordon, 2009, American heart journal.

Reduction of Stroke Incidence After Myocardial Infarction With Pravastatin The Cholesterol and Recurrent Events (CARE) Study Clinical Investigation and Reports

B. Davis, M. Pfeffer, J. Rouleau, 1998 .

Autologous Cardiac Stem Cell Injection in Patients with Hypoplastic Left Heart Syndrome (CHILD Study)

B. Davis, W. Mahle, Michael E. Davis, 2022, Pediatric Cardiology.

TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia

Scott T. Miller, Jamie L. Coleman, B. Davis, 2015 .

Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults ALLHAT-LLT randomized clinical trial

B. Davis, J. Williamson, C. Blaum, 2017 .

Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial.

Dejian Lai, Saif Anwaruddin, Catalin Loghin, 2012, JAMA.

Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).

B. Davis, Jackson T. Wright, J. Cutler, 2002, Journal of clinical hypertension.

Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone

B. Davis, J. Williamson, J. Cutler, 2002, Current controlled trials in cardiovascular medicine.

Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial

B. Davis, J. Williamson, C. Blaum, 2017, JAMA internal medicine.

Factors Considered by Interprofessional Team for Treatment Decision in Hip Fracture with Dementia

C. Ambrose, S. McCurdy, L. Piller, 2019, Journal of the American Geriatrics Society.

Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use.

Barry R Davis, B. Davis, P. Whelton, 2010, Archives of internal medicine.

Two Decades of ICU Utilization and Hospital Outcomes in a Comprehensive Cancer Center

B. Tilley, J. Nates, L. Piller, 2016, Critical care medicine.

Role of Diuretics in the Prevention of Heart Failure: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

B. Davis, J. Cutler, M. Proschan, 2006, Circulation.

Risk of Hospitalized Gastrointestinal Bleeding in Persons Randomized to Diuretic, ACE‐Inhibitor, or Calcium‐Channel Blocker in ALLHAT

B. Davis, J. Williamson, S. Oparil, 2013, Journal of clinical hypertension.

Characteristics and Lipid Distribution of a Large, High‐Risk, Hypertensive Population: The Lipid‐Lowering Component of the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

D. Gordon, N. Wong, L. Haywood, 2003, Journal of clinical hypertension.

The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.

B. Davis, W. Cushman, H. Black, 2007, American heart journal.

Mortality and Morbidity During and After the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial

B. Davis, P. Whelton, S. Oparil, 2012, Journal of clinical hypertension.

Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.

B. Davis, P. Whelton, Mahboob Rahman, 2012, Clinical journal of the American Society of Nephrology : CJASN.

Long-Term Follow-Up of Participants With Heart Failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

B. Davis, S. Oparil, W. Cushman, 2011, Circulation.

Heart Failure in ALLHAT: Did Blood Pressure Medication at Study Entry Influence Outcome?

B. Davis, J. Cutler, R. Grimm, 2009, Journal of clinical hypertension.

Simultaneous population enrichment and endpoint selection in phase 3 randomized controlled trials: An adaptive group sequential design with two binary alternative primary endpoints

Jaejoon Song, A. Sinha, L. Piller, 2023, Communications in Statistics - Theory and Methods.

Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]).

B. Davis, S. Oparil, L. Haywood, 2016, The American journal of cardiology.

Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination Project

Barry R Davis, B. Davis, P. Whelton, 2009, Clinical trials.

Adverse association between diabetic retinopathy and cardiac structure and function.

R. Klein, B. Klein, B. Klein, 2009, American heart journal.

Comparison of the global statistical test and composite outcome for secondary analyses of multiple coronary heart disease outcomes.

S. Baraniuk, A. Sinha, L. Piller, 2012, Progress in cardiovascular diseases.

Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT.

B. Davis, J. Cutler, W. Cushman, 2017, Journal of the National Medical Association.

Xianglin L. Du, C. Fuller, L. Piller, 2019, Head & neck.

Characteristics and Long-Term Follow-Up of Participants with Peripheral Arterial Disease During ALLHAT

B. Davis, P. Whelton, Mahboob Rahman, 2014, Journal of General Internal Medicine.

Prior preterm birth and maternal subclinical cardiovascular disease 4 to 12 years after pregnancy.

R. Ness, K. Sutton-Tyrrell, E. Barinas-Mitchell, 2013, Journal of women's health.

Clinical Implications of the Cervical Papanicolaou Test Results in the Management of Anal Warts in HIV-Infected Women

W. Chan, L. Piller, R. Beasley, 2013, PloS one.

Association between smoking and size of anal warts in HIV-infected women

W. Chan, L. Piller, R. Beasley, 2012, International journal of STD & AIDS.

An evaluation of differences in risk factors for individual types of surgical site infections after colon surgery.

B. Tilley, K. Bilimoria, L. Piller, 2014, Surgery.

Prior Preterm or Small-for-Gestational-Age Birth Related to Maternal Metabolic Syndrome

R. Ness, J. Catov, L. Piller, 2011, Obstetrics and gynecology.

Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

B. Davis, C. Furberg, J. Wright, 2001, Controlled clinical trials.

Comparison of utilization of urgent care and primary care 2011-2015

L. Piller, T. Krause, Cecilia Ganduglia-Cazaban, 2018 .

Longitudinal Sensitivity of Alzheimer’s Disease Severity Staging

Julia S. Benoit, W. Chan, R. Doody, 2020, American journal of Alzheimer's disease and other dementias.

Symptom Burden Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Cancer Survivors

Xianglin L. Du, C. Fuller, D. Rosenthal, 2018, JAMA otolaryngology-- head & neck surgery.

Cost-Effectiveness of Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients with Advanced Ovarian Cancer.

Xianglin L. Du, W. Chan, D. Lairson, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Impact of Hematopoietic Growth Factors on Blood Transfusion Needs, Incidence of Neutropenia, and Overall Survival Among Elderly Advanced Ovarian Cancer Patients Treated With Chemotherapy

Xianglin L. Du, W. Chan, D. Lairson, 2015, International Journal of Gynecologic Cancer.

Use of Hematopoietic Growth Factors and Risk of Thromboembolic and Pulmonary Toxicities in Elderly Patients with Advanced Ovarian Cancer.

Xianglin L. Du, W. Chan, D. Lairson, 2016, Women's health issues : official publication of the Jacobs Institute of Women's Health.

Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 1: Ethical considerations.

G. Ball, L. Piller, M. Silverman, 2011, Contemporary clinical trials.

Long-Term Follow-Up of Participants With Heart Failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

B. Davis, S. Oparil, W. Cushman, 2011, Circulation.

Doris A Taylor, B. Byrne, D. Gordon, 2009, American heart journal.

Long-Term Follow-Up of Participants With Heart Failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

B. Davis, S. Oparil, W. Cushman, 2011, Circulation.

Joint models of dynamics of mothers’ stress and children’s disease

Xiaoying Yu, Wenyaw Chan, Michael D. Swartz, 2018, Commun. Stat. Simul. Comput..

Place of Death among Hospitalized Patients with Cancer at the End of Life.

B. Tilley, J. Nates, L. Piller, 2015, Journal of palliative medicine.

Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).

J. Probstfield, V. Papademetriou, C. Ford, 2002 .